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Abstract
Pleural spread from non-small cell lung cancer is a difficult situation. The average sur-
vival in the situation is about 6–9 months. We investigate the current management of this 
challenging condition. Although, there is no much evidence found in the literature, we 
do see the pleural photodynamic therapy giving some promising light in the dark night. 
However, the patients still require complete neoadjuvant and adjuvant therapies, as well 
as radical tumor resection. Pleural PDT is one of the multi-modality treatments, which 
combined can achieve satisfactory oncological results. The long-term survival can be 
achieved in more than half the patients. However, the side effects of pleural PDT include 
skin hypersensitivity, trachea and esophageal perforation, and ARDS, which we should 
keep in mind.
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1. Introduction
Photodynamic therapy (PDT) is one of the established treatment modality for non-small cell 
lung cancer (NSCLC). Early-stage lung cancer and superficial endobronchial lesions less than 
1 cm in thickness can be effectively treated with external light sources. Thicker lesions and 
peripheral lesions may be amenable to interstitial PDT, where the light is delivered intra-
tumorally. The primary adverse event, phototoxicity, is expected to be minimized with the 
introduction of new photosensitizers that have shown promising results in phase I and II clin-
ical studies. Moreover, the addition of PDT to standard-of-care surgery and chemotherapy 
(or target therapy) can improve survival and outcomes in patients with pleural dissemination. 
Therefore, intra-operative PDT has shown promise in the treatment of non-small cell lung 
cancer with pleural spread.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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The presence of pleural spread in non-small cell lung cancer (NSCLC) without distant metas-
tases was classified as stage III b in the previous International System for Staging Lung 
Cancer [1]. The seventh edition of the TNM classification of lung cancer was published in 
2009, and the changes to the sixth edition of this document were according to proposals 
from the International Association for the Study of Lung Cancer (IASLC). The IASLC lung 
cancer staging project committee suggested that pleural disseminations (pleural nodules or 
malignant pleural effusions) be reclassified to M1a from T4. In patients with pleural carci-
nomatosis, the reported median survival time ranged from 6 to 9 months [2–8]. Currently, 
the management options for pleural spread include chemotherapy, surgery with pleurec-
tomy, and photodynamic therapy. Thymomas are neoplasms arising from epithelial thymic 
cells. They rarely metastasize to distant sites; on the contrary, they more often show pleural 
implantation at diagnosis or during follow-up. Thymoma with pleural spread is also a dif-
ficult clinical situation to manage, and the treatment is controversial [9–11].
Photodynamic therapy (PDT) is an anticancer treatment combining photosensitizer, oxygen, 
and visible light. PDT anticancer effect occurs when the photosensitizer captures light energy 
and transfers that energy to oxygen. The excited oxygen species are responsible for the effect 
and can directly kill tumor cells, damage the tumor blood supply, or both [10]. Porfimer 
sodium (Photofrin; Axcan Pharma Inc, Birmingham, AL, USA), a first-generation photosen-
sitizer that is a mixture of porphyrin monomers and oligomers, is used most often. They are 
activated by 630 nm red light. Successful treatment of malignant mesothelioma by photody-
namic therapy has been reported as a new approach for pleural malignancy dissemination 
[12]. Moreover, as with malignant pleural mesothelioma, PDT may be utilized as part of a 
multi-modality management strategy for non-small cell lung cancer with pleural spread. A 
phase II trial enrolling 22 patients with pleural spread and clinical T4 NSCLC was conducted 
in which patients underwent surgery with complete or partial tumor debulking, followed by 
hemithoracic pleural PDT or PDT alone. The median overall survival was 21.7 months, com-
pared with 6–9 months for similar patients based on historical controls [13].
2. Operative procedures
Thoracotomy was performed for either multiple wedge resection or lobectomy. The particular 
pulmonary resection was chosen by the same criteria as those used for performing resections 
with curative intent in patients with early lung cancer. Anatomic resections (pneumonectomy, 
lobectomy, or segmentectomy) were performed only in patients in whom it was possible to resect 
all gross disease. After finishing lung resection, total parietal pleurectomy was performed sub-
sequently. The parietal pleura were stripped from the bony hemithorax as radical parietal pleu-
rectomy. The mediastinum was debulked of all gross tumor. For thymoma patients, the radical 
thymothymectomy was performed concurrent with radical pleural pleurectomy. The goal was to 
have no visible or palpable tumor left in the affected hemithorax at the end of the operation [14].
We sewed flat photodiodes into seven regions of the pleural space, which include the apex, 
anterior chest wall, posterior chest wall, posterior costophrenic sulcus, anterior costophrenic 
sulcus, posterior mediastinum, and pericardium. Moreover, we handle it with a dosimetry 
system. The dosimetry system provided both the real-time luminescence and the cumulative 
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light dose for the seven regions. The cavity was filled with diluted intralipid solution (0.01%) 
to act as scattering agent, giving a more homogeneous light delivery. The light was delivered 
with an optical fiber sheathed within a modified endotracheal tube. This delivery system was 
moved around the chest cavity until a measured dose of 40 J/cm2 of 630 nm light was recorded 
at all seven regions (Figures 1 and 2). During the light delivery of PDT, the chest retractors 
were removed to avoid shielding. We use 20 L of intralipid solution to maintain a clear intra-
thoracic area and to minimize light absorption affected by hemoglobin. Sterile photodiodes 
were removed from the pleural cavity after completion of light administration. The overall 
time of the light delivery portion of PDT was about 1 h. Then, the operation is completed after 
wound closure and setting two 28 fr chest tubes.
Figure 1. The operator and the 630 nm light source. The operator is hoding the laser light source which can activate 
the photosensitizer in tumor cells. The laser probe is within the endotracheal tube which enhance the convenience of 
irradiation in the pleural space.
Figure 2. The dosimetry system. The dosimetry system provided both the real-time luminescence and the cumulative 
light dose for the seven regions.




The pleural spread of thoracic malignancy is difficult to manage. The standard care of the condi-
tion is non-operative worldwide. Currently, surgery is not considered part of the treatment for 
these patients. It is usually treated with palliative chemotherapy but is barely cured. Surgery 
alone has been ineffective in treating cancer with pleural dissemination because residual micro-
scopic disease remains in the chest cavity, even after what appears to be a “complete” resection 
[2–8]. Photodynamic therapy offers several potential advantages for treating disseminating sur-
face cancer. First, preclinical studies demonstrate a greater retention of photosensitizers in tumor 
compared with normal tissues [15]. Second, the PDT penetrates several millimeters into tissue. 
It results in surface cell killing, while sparing the underlying tissues. Therefore, PDT is suitable 
for the treatment of cancers that have spread to organ surfaces, including pleura or peritoneum 
[16, 17]. Moreover, PDT is a localized therapy that can be performed intraoperatively. Intra-
operative pleural PDT was used as one of the multimodal approaches for treating patients with 
pleural carcinomatosis. The hypothesis was that, upon complete resection of all gross disease, 
immediate intraoperative PDT might be effective in treating the residual microscopic disease. 
For lung cancer, the phase II trial at the University of Pennsylvania proved our point of view. 
It showed 73.3% of 6-month localized disease control for the cohort and a median overall sur-
vival of 21.7 months, compared with 6–9 months survival for similar patients treated with the 
non-operative standard of care and based upon historical controls [13]. Compared with surgery 
without PDT for patients of lung cancer with pleural spread in literature, the outcome of patients 
receiving surgery plus PDT is better [18, 19]. The best median overall survival of the lung can-
cer patients was 39.0 months, conducted by our group (Figure 3) [20]. The comparison of these 
results is listed in Table 1. Therefore, we found that the result was good, and the morbidity was 
acceptable. However, the PDT is only one of the multi-modality treatments, so the adjuvant or 
neoadjuvant therapy is important, too. Our group conducted another experiment about the sig-
nificance of the Epidermal Growth Factor Receptor (EGFR) profile to the PDT-sensitive cancer 
cells [21]. Because tyrosine kinase inhibitor (TKI) was popularly used in the advanced lung can-
cer, we investigated the roles of this two common therapies combined. Although photodynamic 
therapy (PDT) has been demonstrated to be an effective minimally invasive treatment modality 
for thoracic cancer, the molecular action in thoracic cancer during PDT is hardly known. EGFR 
has been known to downregulate in various cancer cells during PDT. In the study, we investi-
gated the effects of Photofrin-mediated PDT on cell death and expression of EGFR in CE48T/
VGH (CE48T) squamous carcinoma cells. We found that the photosensitizer Photofrin in the 
absence of light exposure can downregulate the expression of EGFR at both transcription and 
translation levels. Higher concentrations of Photofrin result in cytotoxicity, whereas lower doses 
of Photofrin inhibit EGFR expression under dark control without inducing significant cell death. 
This Photofrin-associated inhibition of EGFR was repeated in lung cancer, cervical cancer, and 
glioblastoma cells. Another squamous cell carcinoma cell line CE81T/VGH (CE81T) was found 
to be resistant to Photofrin-induced inhibition of EGFR as well as to Photofrin-mediated dark 
toxicity compared with CE48T. The resistance to the cytotoxicity in CE81T cells became insignifi-
cant when the Photofrin-treated cells were further irradiated by red light (Photofrin-PDT). We 
suggest Photofrin modulates the expression of EGFR in cancer cells. However, efficient cell death 
still requires the combination of Photofrin and light irradiation in squamous cell carcinoma cells.
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4. Conclusion
Photodynamic therapy is a promising treatment modality for thoracic malignancy. With 
proper patient selection, intrapleural photodynamic therapy for pleural spread in patients 
with lung cancer or thymoma is feasible and may provide a survival benefit.
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Figure 3. Kaplan-Meier survival analysis of the patients undergoing PDT vs. non-PDT for pleural spread (P = 0.047).
Studies Year Country Mean age ± SD (years) No. of patients 5-year survival rate (%)
Wang et al. 2011 Taiwan 62.3 ± 11.2 90 21.7
Mordant et al. 2011 France 59.0 ± 8.8 32 16.0
Chen et al. 2013 Taiwan 51.9 ± 11.9 10 56.3
Table 1. Comparison with other series for lung cancer patients.
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